AstraZeneca (AZN LN) CEO says the government is moving in the right direction with regards to drug pricing and talks will occur between Europe and US of similar nature, via conference call

AstraZeneca's CEO indicates a positive shift in government drug pricing policy, suggesting ongoing discussions between the US and Europe that may impact market dynamics.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

Amphenol (APH) Q1 2026 (USD): Adj. EPS 1.06 (exp. 0.94), Revenue 7.6bln (exp. 7.08bln)

Iran has warned that continued US maritime piracy will soon be met with “practical and unprecedented military action,” high-ranking security source told Press TV

AstraZeneca (AZN LN) CEO says the government is moving in the right direction with regards to drug pricing and talks will occur between Europe and US of similar nature, via conference call

AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)

Pakistan's PM says efforts to achieve peace and ceasefire are ongoing, Al Arabiya reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could signal potential regulatory changes favorable to the pharmaceutical sector, influencing investor sentiment towards similar companies. Keep an eye on how this may reshape competitive strategies in the biotech landscape.

Related headlines

The whole workspace, free to try.

Try it free